The Latest Cardiac and Vascular News
LAKE OSWEGO, Ore., Dec. 16, 2020 /PRNewswire/ — BIOTRONIK today announced FDA clearance and availability of the Vital Data Sensor, which identifies body temperature increases potentially associated with fever, in the new BIOMONITOR IIIm injectable cardiac monitor (ICM), as shown in a published case report1. Physicians will now have access to daily reports on […]
Contract Offers Increased Savings to More than Half of Nation’s Healthcare Organizations for BIOTRONIK’s Coronary Products Including the Orsiro Drug Eluting Stent LAKE OSWEGO, Ore., June 1, 2020 /PRNewswire/ — BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven, healthcare performance improvement company in the United States. […]
A New Strategic Alliance Between BIOTRONIK, A Leader In Cardiac Rhythm Management, and Acutus Medical, Electrophysiology Innovator, Expected to Offer More Efficient and Effective Diagnosis and Treatment for Arrhythmia Patients CARLSBAD, Calif. and BERLIN, May 20, 2020 /PRNewswire/ — Acutus Medical and BIOTRONIK today announced a new alliance to provide a comprehensive portfolio of electrophysiology, mapping, ablation and […]
Sub-Analysis Of Large Multi-Center Study Shows DX Technology Provides Similar CRT Responses To Conventional Three-Lead System With Reduced Risk LAKE OSWEGO, Ore., May 27, 2020 /PRNewswire/ — Results recently published in the Journal of Cardiovascular Electrophysiology confirm that BIOTRONIK’s unique two-lead CRT-DX system provides equivalent therapy to more conventional three-lead systems. CRT-DX systems consist of […]
Former Mayo Clinic Physician Administrator Joins to Drive Collaboration between Physicians, Clinical Research, and the Continued Development of Life-Improving Technology LAKE OSWEGO, Ore., Jan. 27, 2020 /PRNewswire/ — BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer. Dr. Hayes will oversee the development of BIOTRONIK’s cardiovascular solutions with a […]
Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations LAKE OSWEGO, Ore., April 10, 2019 /PRNewswire/ — BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2 More than 800,000 percutaneous coronary intervention procedures are performed annually […]
BIOTRONIK’s Ultrathin-Strut Drug-Eluting Stent Soon Available in China Following Market Approval BEIJING, China and BUELACH, Switzerland, October 30, 2019 – BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients […]
CASTLE PINES, Colo., Sept. 16, 2019 /PRNewswire/ — Proximo Medical, LLC today announced that it is the commercial partner for BIOTRONIK, Inc.’s peripheral vascular intervention (PVI) platform in select United States markets. BIOTRONIK, a global medical technology company headquartered in Berlin, Germany with U.S. offices in New York City and Lake Oswego, Oregon, develops trusted and innovative cardiovascular and endovascular solutions. Proximo Medical is […]
LAKE OSWEGO, Ore., July 31, 2019 /PRNewswire/ — BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is used in emergency situations to create a physical barrier to seal life-threatening perforated coronary arteries without the need for invasive surgery. In September […]
LAKE OSWEGO, Ore., July 8, 2019 /PRNewswire/ — BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatment. Early detection of arrhythmia through ICMs enables physician intervention before adverse outcomes occur. Atrial fibrillation […]
